E-032 Endovascular therapy of anterior communicating artery micro-aneurysms: outcomes and complication rates – data from the SMART registry. (22nd July 2019)

• Record Type: Journal Article
• Authors: Almallouhi, E; Sattur, M; Al Kasab, S; Anadani, M; Spiotta, A
• Is Part Of: Journal of neurointerventional surgery. Volume 11(2019)Supplement 1
• Page Start: A64
• Page End: A64
• Publication Date: 2019-07-22
• Subjects: Nervous system -- Surgery -- Periodicals; Cerebrovascular disease -- Surgery -- Periodicals; 617.48
• DOI: 10.1136/neurintsurg-2019-SNIS.107
• Languages: English
• ISSNs: 1759-8478

Abstract

Abstract : Background: Previous studies have suggested that anterior communicating artery (ACoA) microaneurysms (<4 mm) were associated with a higher rate of peri-procedure complications when compared to ACoA aneurysms that were 4 mm or larger. We aimed to evaluate the outcomes of patients with unruptured ACoA aneurysms according to aneurysm size in a large, contemporary registry. Methods: We reviewed the prospective, multicenter SMART registry to identify patients with unruptured ACoA aneurysm who were treated with endovascular embolization using the SMART coils. We aimed to report the angiographic outcome and peri-procedural complications of endovascular embolization of ACoA aneurysm according to the aneurysm size (<4 mm vs. ≥4 mm). Results: Out of 906 patients included in the SMART registry, 146 (16.1%) patients had unruptured ACoA aneurysms (age 60.8 ±11.9 yr and 61.6% were females). Of those ACoA, 43 were <4 mm (micro-aneurysms). Microaneurysms were more likely to be wide-necked (84.6% vs. 54.2%, P 0.016). No difference was found in the rate of peri-procedural device related adverse effects, periprocedural mortality, rate of adequate occlusion immediately and at one-year, length of hospitalization and one-year recanalization rate between both groups (table 1). Conclusions: Endovascular treatment of unruptured ACoA microaneurysms is associated with similar successful embolization and complication rates compared to larger size ACoA aneurysms. Disclosures: E. Almallouhi: None. M. Sattur: None. S. Al kasab: None. M. Anadani: None. A. Spiotta: 2; C; Penumbra, Cerenovus, Minnetronix.